OTS.at - aktuelle Inhalte in Text, Bild, Ton und Video

Grünenthal Group

Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich

Aachen, Germany (OTE) - Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research...

16.07.2026, 09:39:03
/
OTE0001

Grünenthal Group

Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy

Aachen (OTE) - Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment...

08.07.2026, 09:57:02
/
OTE0001

Grünenthal Group

Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist

Aachen (OTE) - Aachen (ots)

29.06.2026, 11:47:32
/
OTE0001

Grünenthal Group

Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm

Aachen, Germany & Yeoju, South Korea (OTE) - Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its...

05.03.2026, 08:30:02
/
OTE0001

Grünenthal Group

Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands

Aachen, Germany (OTE) - - Grünenthal acquired Kyowa Kirin International's 49% stake in 'Grünenthal Meds', a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International....

02.03.2026, 09:55:32
/
OTE0001

Grünenthal Group

Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect

Aachen, Germany & Victoria, Australia (OTE) - Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique...

24.02.2026, 06:06:03
/
OTE0001

Grünenthal Group

Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development

Aachen, Germany (OTE) - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational...

18.02.2026, 10:48:02
/
OTE0001

Grünenthal Group

Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors

Aachen (OTE) - Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive...

04.09.2025, 10:03:04
/
OTE0001

Grünenthal Group

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia

Aachen, Germany (OTE) - Aachen, Germany (ots)

02.06.2025, 10:00:33
/
OTE0002

Grünenthal Group

Maren Thurow starts as new Head Global Communications at Grünenthal

Aachen (OTE) - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department...